Monday 16 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was -28.7% in Q3 FY26, the lowest of these four quarters. ROE, at 0.0%, is far above it because equity is small against the capital the business uses.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 0.0% | 0.0% | 0.0% | 0.0% |
| ROIC | 0.0% | 0.0% | 0.0% | −28.7% |
Debt
Net debt is 11.58× a year’s EBITDA.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Net debt / EBITDA | 12.8× | 5.3× | 7.7× | 11.6× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+2 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
(28.66%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(19.20%) | (86.05%) | (112.84%) | (78.60%) | |
Free Cash Flow per Share |
(0.92) | (3.26) | (1.05) | (0.52) | |
Free Cash Flow |
(47.78) | (24.15) | (7.20) | (2.01) | |
| Other line items | |||||
Cash ROIC |
(5.64%) | (89.04%) | (290.56%) | (8.65%) | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.73 | 0.25 | 0.09 | 0.03 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.92) | (3.26) | (1.05) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 12 Nov 2026